Industry News

We gather useful links to news on the thousands of companies listed in the directory either directly from the company or independently from authoritative publicly available sources e.g. industry newspapers, journals and websites. You can use this news database to search these links. Search either by the name of company or by country/place or key word or combination thereof.

Search Term

Save This Search | View as Grid | Order by Recently Added | Order by Company Name

  • Total Results: 1,045
  • Total Pages: 53

Merck & Co 17 May 2019


Merck ‘evaluating global footprint’ with $1.2bn manufacturing restructure


Merck continues its multi-year restructuring process with a program that could cost up to $1.2bn and has a provisional end date of 2023.



View original story »


Indena SpA 17 May 2019




After demonstrating its activity, efficacy and safety profile in the field of sports nutrition, a pilot non-interaction study confirms the high tolerability of Quercefit in individuals assuming antiplatelet agents, anticoagulants or living with diabetes.


View original story »


Pfizer 01 May 2019


Pfizer reports first-quarter profit that beats estimates


Strong vaccine and cancer drug sales help Merck top earnings expectations and send its shares higher


View original story »


PolyPeptide Laboratories 27 Apr 2019


Panel Discussion on Pharma and Chemical Supply Chain

Robert Hagopian, Chemistry Today - Pharma Horizon, Jan./Feb. 2019, Mar 2019

View original story »


Vetter Pharma International GmbH 26 Apr 2019


Clinical Manufacturing on Time and within Budget


 In 2018, a record of 55 submitted drugs received approval from the FDA. Key to this achievement was a focus on reaching clinical end points as well as compliance with good and high-quality manufacturing practice. Well-orchestrated cGMP manufacturing can help avoid manufacturing issues primarily in the clinical phases as well as in discussing potential projects with partners or key stakeholders.


View original story »


Actex Pharma Services 26 Apr 2019


HPAPI market to reach $26bn in 2023: CDMOs need to ‘gear up’ to support future demands


Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.



View original story »


WuXi Biologics 25 Apr 2019


WuXi Biologics is producing a newly approved HIV med in the first Chinese biologics plant approved by the FDA


This week, the FDA approved Trogarzo (ibalizumab-uiyk), the first HIV therapy with a novel mechanism of action in more than 10 years and the first drug developed by Taiwan-based TaiMed Biologics. It also represents a first for WuXi Biologics, the Chinese company that will produce it at a biologics plant near Shanghai.


View original story »


WuXi Biologics 25 Apr 2019


WuXi Biologics Completes First FDA Routine GMP Inspection


Production of HIV drug Trogarzo is now approved at the Wuxi facility


View original story »


Cambrex Profarmaco 25 Apr 2019


Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan


East Rutherford, NJ – March 14, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000 liter reactor into one of its cGMP manufacturing facilities at…


Read more on this story »


Cambrex 25 Apr 2019


Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA


East Rutherford, NJ – April 10, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA. The 6,000 sq. ft. facility is currently undergoing validation and will…


Read more on this story »


Avidity Biosciences 25 Apr 2019


Lilly, Avidity Biosciences Enter Global R&D Alliance


Lilly and Avidity Biosciences Announce Licensing and Research Collaboration

  • Collaboration will pursue therapeutic targets focused on immunology and other indications
  • Avidity to receive an upfront payment of $20 million and an investment of $15 million
  • Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties

    Read more on this story »


Almac Sciences 25 Apr 2019


Almac Group Further Expands Global Analytical Services Capability


Currently employing over 150 highly skilled analysts working in GMP / GLP environments from its 3 locations in Craigavon, UK; Athlone, Ireland; and Souderton, Pennsylvania, North America, Almac is positioned as the partner of choice with significant experience in a wide range of analytical services. 


View original story »


Poseida Therapeutics Inc 24 Apr 2019


Poseida Therapeutics. has raised $142 million (€126 million) in C funding.


SAN DIEGO, April 22, 2019 — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced closing of a Series C financing round, raising $142 million led by a $75 million equity investment from Novartis Pharma AG, and joined by several new investors including Aisling Capital Management, Pentwater Capital Management, Perceptive…


Read more on this story »


Amryt Pharma 24 Apr 2019


Amryt gets 2019 off to strong start following 13% revenue rise in 2018


Lojuxta revenues driven by UK, France reimbursement approval

Irish pharmaceutical company Amryt said its revenues rose 13.3 per cent in 2018 to €14.5 million and the strong momentum continued into the first quarter of this year as revenues from its main drug Lojuxta picked up.


View original story »


Fusion Antibodies plc 24 Apr 2019


Fusion Antibodies confirms second-half pick-up in revenue


Orders and revenues rise in Belfast-based firm in final six months of financial year. Revenues for the second half of the year rose to £1.5 million (€1.7 million), compared with £700,000 in the first six months of the year, and £1.3 million for the same period a year earlier.


View original story »


Schott Glass AG 23 Apr 2019


SCHOTT Invests $1B in Pharmaceutical Packaging


SCHOTT Invests $1B in Pharmaceutical Packaging Dr. Heinricht of SCHOTT discusses the investment, growth markets, and how pharma and biopharma needs are changing


View original story »


Paragon Bioservices 22 Apr 2019


Paragon to Build Second GMP Mfg


Facility Expands collaboration in manufacturing design and operation with Sarepta Therapeutics


View original story »


Schott Glass AG 22 Apr 2019


SCHOTT strengthens footprint in pharmaceutical tubing business in South America


As part of its global growth strategy, the technology group SCHOTT is investing BRL 50 million in its pharmaceutical tubing production in Rio de Janeiro in the next two years. The invest covers the latest update of the company’s perfeXion® process – a 100 percent on-line inspection system, which examines every single tube – as well as implementing state-of-the-art production technology in glass-melting furnaces. It follows a previous modernization project, which has…


Read more on this story »


MS Pharma 19 Apr 2019


MS Pharma Announces Acquisition of Genepharm


MS Pharma, a fast growing pharmaceutical company based in Jordan and operating across the Middle East, Turkey and Africa, announced today that it has entered into an agreement to acquire 100% of the outstanding shares in Genepharm, a leading European pharmaceutical company. Genepharm’s senior management will remain with the business and help guide the company through the next phase of its growth.  The transaction is expected to close by the end of April.


View original story »


GSK 10 Apr 2019


Pharma GSK's Dovato chalks up first 2-drug regimen nod for new HIV patients.


Approval based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, traditional, three-drug regimen through 48 weeks, with no cases of resistance.[1]


Read more on this story »

  • Total Results: 1,045
  • Total Pages: 53

About Us

Actex Pharma Services is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at


Get in Touch

The Pharmaceutical Services Directory


© 2019 Actex Pharma Services | All Rights Reserved.